Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1979-8-16
pubmed:abstractText
1 Measurement of changes in trans-mural rectal potential difference (t.m.r.p.d.) and plasma aldosterone levels have been used in a comparison of the extra-renal activities of spironolactone and its major metabolite canrenone. 2 A characteristic pressure artifact was observed during measurement of t.m.r.p.d. When pressure artifacts were eliminated, there was a log-linear relationship between increasing doses of intravenous aldosterone and maximum increase in t.m.r.p.d. 3 Pre-treatment for 5 days with spironolactone or canrenone produced a similar attenuation of the increase in t.m.r.p.d. produced by infused aldosterone, suggesting that canrenone is the active metabolite of spironolactone in the rectum. This is in contrast to the significantly greater renal activity of spironolactone that has been demonstrated after a similar treatment period. Neither antagonist treatment produced significant changes in pre-infusion plasma aldosterone concentrations. 4 The need for assay of the extra-renal activities of aldosterone antagonists in the assessment of their therapeutic potential is discussed.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-13774838, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-13813355, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-13975085, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-14171763, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-23137, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-237802, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-240933, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-4267313, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-4338121, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-4712657, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-4729203, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-4829862, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-5069733, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-5428856, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-5496690, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-5547796, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-5639362, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-5822526, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-752013, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-780038, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-858213, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-921083, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-973942, http://linkedlifedata.com/resource/pubmed/commentcorrection/444357-976190
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
385-92
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1979
pubmed:articleTitle
A comparison of some extra-renal effects of spironolactone and canrenone.
pubmed:publicationType
Journal Article, Comparative Study